

NOVO NORDISK A S
Form 6-K
June 11, 2013

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

June 10, 2013

NOVO NORDISK A/S

(Exact name of Registrant as specified in its charter)

Novo Allé

DK- 2880, Bagsvaerd

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F

Form 20-F Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-_____

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 10 June 2013 – On 3 May 2013, Novo Nordisk initiated a share repurchase programme in accordance with the provisions of the European Commission’s regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 14.0 billion to be executed during a 12-month period beginning 31 January 2013.

Under the programme initiated 3 May 2013, Novo Nordisk will repurchase B shares for an amount up to DKK 3.0 billion in the period from 6 May 2013 to 6 August 2013.

Since the announcement as of 3 June 2013, the following transactions have been made under the programme:

	Number of shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	876,500		859,387,583
3 June 2013	60,000	930.28	55,816,536
4 June 2013	40,000	931.18	37,247,068
6 June 2013	55,000	932.34	51,278,436
7 June 2013	50,000	914.04	45,702,190
Accumulated under the programme	1,081,500		1,049,431,813

Transactions related to Novo Nordisk’s incentive programmes have resulted in a net sale by Novo Nordisk of 488 B shares in the period from 3 June 2013 to 7 June 2013. The shares in these transactions were not part of the Safe Harbour repurchase programme.

With the transactions stated above, Novo Nordisk owns a total of 14,218,660 treasury shares, corresponding to 2.6% of the share capital. The total amount of shares in the company is 550,000,000 including treasury shares.

Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark

Telephone: CVR no:
+45 4444 8888 24 25 67 90
Internet:
www.novonordisk.com

Company announcement No 43 / 2013

Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12-month period beginning 31 January 2013. As of 7 June 2013, Novo Nordisk has repurchased a total of 6,693,310 B shares equal to a transaction value of DKK 6,552,143,247.

Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 35,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

Further information

Media:

Anne Margrethe Hauge
Ken Inchausti (US)

+45 4442 3450
+1 609 514 8316

amhg@novonordisk.com
kiau@novonordisk.com

Investors:

Kasper Roseeuw Poulsen
Frank Daniel Mersebach
Lars Borup Jacobsen
Jannick Lindegaard (US)

+45 4442 4303
+45 4442 0604
+45 3075 3479
+1 609 786 4575

krop@novonordisk.com
fdni@novonordisk.com
lbpj@novonordisk.com
jlis@novonordisk.com

Novo Nordisk A/S
Investor Relations
Novo Allé
2880 Bagsværd
Denmark

Telephone: CVR no:
+45 4444 8888 24 25 67 90
Internet:
www.novonordisk.com

Company announcement No 43 / 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.

Date: June 10, 2013

NOVO NORDISK A/S

Lars Rebien Sørensen,

President and Chief Executive Officer